Hu immunolabeling as a marker of neural and neuroendocrine differentiation in normal and neoplastic human tissues: Assessment using a recombinant anti-Hu Fab fragment

Sakir Gultekin, Juan Rosai, Alexis Demopoulos, Yvo F. Graus, Jerome B. Posner, Josep Dalmau, Marc K. Rosenblum

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The recombinant antibody fragment Fab GLN 495 recognizes an epitope shared by members of the neuron-associated Hu protein family (including HuC, HuD, and HelN1). This novel reagent labels the nuclei of neurons throughout the peripheral and central neuraxes and has been shown to recognize pulmonary small cell carcinomas and central nervous system (CNS) tumors of mature neuronal phenotype or neuronogenic differentiating capacity. Using this Fab fragment, we have undertaken a systematic survey of normal human tissues and an assessment of 554 non-CNS tumor samples for immunohistochemical evidence of Hu expression. Adrenomedullary cells, pancreatic islet cells, paraganglial chief cells, isolated adenohypophyseal cells, and spermatogonia were the only nonneuronal normal tissue elements to bind Fab GLN 495. In addition to labeling all 10 small cell carcinomas studied (six of which were extrapulmonary in origin), this recombinant anti-Hu Fab proved immunoreactive with neuroblastomas (four/four), esthesioneuroblastomas (one/one), typical (three/four) and atypical (one/four) pulmonary carcinoids, pancreatic islet cell tumors (two/six), large-cell neuroendocrine carcinoma of lung (one/four), Merkel cell tumors (two/three), medullary carcinomas of the thyroid (four/six), pheochromocytomas (two/four) and paragangliomas (four/four). Nonneural/neuroendocrine tumor labeling was restricted to the neuronal and immature neuroepithelial components of teratomas, to extraskeletal myxoid chondrosarcomas (three/four) and to small subsets of cells within examples of renal rhabdoid tumor (one/four), desmoplastic small cell tumor (one/four), alveolar rhabdomyosarcoma (two/four), Ewing sarcoma/PNET (two/nine), and Wilms tumor (one/four). Immunoreactivity was principally nuclear, with variable cytoplasmic labeling. Our findings support the largely restricted expression of Hu by neural/neuroendocrine neoplasms, suggest a potential role for Fab GLN 495 in the identification of small cell carcinomas irrespective of primary site, and support a recent proposal that at least some extraskeletal myxoid 'chondrosarcomas' actually represent neuroendocrine tumors of soft parts.

Original languageEnglish (US)
Pages (from-to)109-117
Number of pages9
JournalInternational Journal of Surgical Pathology
Volume8
Issue number2
StatePublished - Apr 2000
Externally publishedYes

Fingerprint

Immunoglobulin Fab Fragments
Small Cell Carcinoma
Neuroendocrine Tumors
Islets of Langerhans
Lung
Desmoplastic Small Round Cell Tumor
Alveolar Rhabdomyosarcoma
Olfactory Esthesioneuroblastoma
Rhabdoid Tumor
Nervous System Neoplasms
Merkel Cell Carcinoma
Neuroendocrine Carcinoma
Neurons
Large Cell Carcinoma
Primitive Neuroectodermal Tumors
Paraganglioma
Central Nervous System Neoplasms
Immunoglobulin Fragments
Spermatogonia
Ewing's Sarcoma

Keywords

  • Anti-Hu
  • Antineuronal autoantibodies
  • Human tumors
  • Neuroendocrine tumors
  • Paraneoplastic syndromes
  • Recombinant antibodies
  • Small cell carcinoma

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery

Cite this

Hu immunolabeling as a marker of neural and neuroendocrine differentiation in normal and neoplastic human tissues : Assessment using a recombinant anti-Hu Fab fragment. / Gultekin, Sakir; Rosai, Juan; Demopoulos, Alexis; Graus, Yvo F.; Posner, Jerome B.; Dalmau, Josep; Rosenblum, Marc K.

In: International Journal of Surgical Pathology, Vol. 8, No. 2, 04.2000, p. 109-117.

Research output: Contribution to journalArticle

Gultekin, Sakir ; Rosai, Juan ; Demopoulos, Alexis ; Graus, Yvo F. ; Posner, Jerome B. ; Dalmau, Josep ; Rosenblum, Marc K. / Hu immunolabeling as a marker of neural and neuroendocrine differentiation in normal and neoplastic human tissues : Assessment using a recombinant anti-Hu Fab fragment. In: International Journal of Surgical Pathology. 2000 ; Vol. 8, No. 2. pp. 109-117.
@article{ce04be21d19c4293857d599da0483e30,
title = "Hu immunolabeling as a marker of neural and neuroendocrine differentiation in normal and neoplastic human tissues: Assessment using a recombinant anti-Hu Fab fragment",
abstract = "The recombinant antibody fragment Fab GLN 495 recognizes an epitope shared by members of the neuron-associated Hu protein family (including HuC, HuD, and HelN1). This novel reagent labels the nuclei of neurons throughout the peripheral and central neuraxes and has been shown to recognize pulmonary small cell carcinomas and central nervous system (CNS) tumors of mature neuronal phenotype or neuronogenic differentiating capacity. Using this Fab fragment, we have undertaken a systematic survey of normal human tissues and an assessment of 554 non-CNS tumor samples for immunohistochemical evidence of Hu expression. Adrenomedullary cells, pancreatic islet cells, paraganglial chief cells, isolated adenohypophyseal cells, and spermatogonia were the only nonneuronal normal tissue elements to bind Fab GLN 495. In addition to labeling all 10 small cell carcinomas studied (six of which were extrapulmonary in origin), this recombinant anti-Hu Fab proved immunoreactive with neuroblastomas (four/four), esthesioneuroblastomas (one/one), typical (three/four) and atypical (one/four) pulmonary carcinoids, pancreatic islet cell tumors (two/six), large-cell neuroendocrine carcinoma of lung (one/four), Merkel cell tumors (two/three), medullary carcinomas of the thyroid (four/six), pheochromocytomas (two/four) and paragangliomas (four/four). Nonneural/neuroendocrine tumor labeling was restricted to the neuronal and immature neuroepithelial components of teratomas, to extraskeletal myxoid chondrosarcomas (three/four) and to small subsets of cells within examples of renal rhabdoid tumor (one/four), desmoplastic small cell tumor (one/four), alveolar rhabdomyosarcoma (two/four), Ewing sarcoma/PNET (two/nine), and Wilms tumor (one/four). Immunoreactivity was principally nuclear, with variable cytoplasmic labeling. Our findings support the largely restricted expression of Hu by neural/neuroendocrine neoplasms, suggest a potential role for Fab GLN 495 in the identification of small cell carcinomas irrespective of primary site, and support a recent proposal that at least some extraskeletal myxoid 'chondrosarcomas' actually represent neuroendocrine tumors of soft parts.",
keywords = "Anti-Hu, Antineuronal autoantibodies, Human tumors, Neuroendocrine tumors, Paraneoplastic syndromes, Recombinant antibodies, Small cell carcinoma",
author = "Sakir Gultekin and Juan Rosai and Alexis Demopoulos and Graus, {Yvo F.} and Posner, {Jerome B.} and Josep Dalmau and Rosenblum, {Marc K.}",
year = "2000",
month = "4",
language = "English (US)",
volume = "8",
pages = "109--117",
journal = "International Journal of Surgical Pathology",
issn = "1066-8969",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Hu immunolabeling as a marker of neural and neuroendocrine differentiation in normal and neoplastic human tissues

T2 - Assessment using a recombinant anti-Hu Fab fragment

AU - Gultekin, Sakir

AU - Rosai, Juan

AU - Demopoulos, Alexis

AU - Graus, Yvo F.

AU - Posner, Jerome B.

AU - Dalmau, Josep

AU - Rosenblum, Marc K.

PY - 2000/4

Y1 - 2000/4

N2 - The recombinant antibody fragment Fab GLN 495 recognizes an epitope shared by members of the neuron-associated Hu protein family (including HuC, HuD, and HelN1). This novel reagent labels the nuclei of neurons throughout the peripheral and central neuraxes and has been shown to recognize pulmonary small cell carcinomas and central nervous system (CNS) tumors of mature neuronal phenotype or neuronogenic differentiating capacity. Using this Fab fragment, we have undertaken a systematic survey of normal human tissues and an assessment of 554 non-CNS tumor samples for immunohistochemical evidence of Hu expression. Adrenomedullary cells, pancreatic islet cells, paraganglial chief cells, isolated adenohypophyseal cells, and spermatogonia were the only nonneuronal normal tissue elements to bind Fab GLN 495. In addition to labeling all 10 small cell carcinomas studied (six of which were extrapulmonary in origin), this recombinant anti-Hu Fab proved immunoreactive with neuroblastomas (four/four), esthesioneuroblastomas (one/one), typical (three/four) and atypical (one/four) pulmonary carcinoids, pancreatic islet cell tumors (two/six), large-cell neuroendocrine carcinoma of lung (one/four), Merkel cell tumors (two/three), medullary carcinomas of the thyroid (four/six), pheochromocytomas (two/four) and paragangliomas (four/four). Nonneural/neuroendocrine tumor labeling was restricted to the neuronal and immature neuroepithelial components of teratomas, to extraskeletal myxoid chondrosarcomas (three/four) and to small subsets of cells within examples of renal rhabdoid tumor (one/four), desmoplastic small cell tumor (one/four), alveolar rhabdomyosarcoma (two/four), Ewing sarcoma/PNET (two/nine), and Wilms tumor (one/four). Immunoreactivity was principally nuclear, with variable cytoplasmic labeling. Our findings support the largely restricted expression of Hu by neural/neuroendocrine neoplasms, suggest a potential role for Fab GLN 495 in the identification of small cell carcinomas irrespective of primary site, and support a recent proposal that at least some extraskeletal myxoid 'chondrosarcomas' actually represent neuroendocrine tumors of soft parts.

AB - The recombinant antibody fragment Fab GLN 495 recognizes an epitope shared by members of the neuron-associated Hu protein family (including HuC, HuD, and HelN1). This novel reagent labels the nuclei of neurons throughout the peripheral and central neuraxes and has been shown to recognize pulmonary small cell carcinomas and central nervous system (CNS) tumors of mature neuronal phenotype or neuronogenic differentiating capacity. Using this Fab fragment, we have undertaken a systematic survey of normal human tissues and an assessment of 554 non-CNS tumor samples for immunohistochemical evidence of Hu expression. Adrenomedullary cells, pancreatic islet cells, paraganglial chief cells, isolated adenohypophyseal cells, and spermatogonia were the only nonneuronal normal tissue elements to bind Fab GLN 495. In addition to labeling all 10 small cell carcinomas studied (six of which were extrapulmonary in origin), this recombinant anti-Hu Fab proved immunoreactive with neuroblastomas (four/four), esthesioneuroblastomas (one/one), typical (three/four) and atypical (one/four) pulmonary carcinoids, pancreatic islet cell tumors (two/six), large-cell neuroendocrine carcinoma of lung (one/four), Merkel cell tumors (two/three), medullary carcinomas of the thyroid (four/six), pheochromocytomas (two/four) and paragangliomas (four/four). Nonneural/neuroendocrine tumor labeling was restricted to the neuronal and immature neuroepithelial components of teratomas, to extraskeletal myxoid chondrosarcomas (three/four) and to small subsets of cells within examples of renal rhabdoid tumor (one/four), desmoplastic small cell tumor (one/four), alveolar rhabdomyosarcoma (two/four), Ewing sarcoma/PNET (two/nine), and Wilms tumor (one/four). Immunoreactivity was principally nuclear, with variable cytoplasmic labeling. Our findings support the largely restricted expression of Hu by neural/neuroendocrine neoplasms, suggest a potential role for Fab GLN 495 in the identification of small cell carcinomas irrespective of primary site, and support a recent proposal that at least some extraskeletal myxoid 'chondrosarcomas' actually represent neuroendocrine tumors of soft parts.

KW - Anti-Hu

KW - Antineuronal autoantibodies

KW - Human tumors

KW - Neuroendocrine tumors

KW - Paraneoplastic syndromes

KW - Recombinant antibodies

KW - Small cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0034046989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034046989&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0034046989

VL - 8

SP - 109

EP - 117

JO - International Journal of Surgical Pathology

JF - International Journal of Surgical Pathology

SN - 1066-8969

IS - 2

ER -